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1. Abstract 
 
Tyrosine kinase 2 (TYK2) is one of the four mammalian receptor-associated Janus kinases (JAKs), 
which together with signal transducers and activators of transcription (STATs) constitute the 
JAK/STAT pathway, a crucial signaling route utilized by many cytokines and growth factors. TYK2 is 
critically involved in the innate and adaptive immune defense against viruses and other pathogens. 
Cytomegaloviruses, members of the Herpesviridae family, had great evolutionary success in evading 
their host’s immune systems. Human Cytomegalovirus (HCMV) is prevalent in most populations 
worldwide, causes the majority of infection-related congenital birth defects and is responsible for 
considerable morbidity and mortality in immune suppressed patients. TYK2 has been shown to be a 
key factor in the defense against murine Cytomegalovirus (MCMV). The general aim of the project is 
to investigate cell type-specific functions of TYK2 in MCMV defense with a special emphasis on 
dendritic cells (DC) and macrophages. To this end, conditional TYK2 knockout mice (TYK2fl/fl) have 
been generated in the laboratory and crossed with mice expressing cre recombinase transgene under 
the control of cell type-specific (i.e. CD11c, LysM) promoters. The topic of this diploma thesis was to 
characterize TYK2CD11c mice with respect to TYK2 deletion efficiencies in DCs and to analyze the 
effect on anti-MCMV defense. We could show highly efficient deletion of TYK2 in bone 
marrow-derived DCs (BMDCs) and in freshly isolated splenic DCs. Similar to what has been shown in 
macrophages, we found a strongly increased MCMV replication in DCs derived from TYK2CD11c and 
TYK2/ (i.e. ubiquitous deletion of TYK2) mice in vitro. This was accompanied by reduced activation 
of STAT1 and STAT2 and thus most likely reflects impaired autocrine/paracrine type I interferon (IFN) 
signaling. Upon MCMV infections in vivo, we found increased viral load in livers of TYK2CD11c 
compared to TYK2fl/fl and TYK2LysM mice at 3 days post infection. Surprisingly, this was only observed 
upon low-dose infection and virus was almost entirely cleared from livers at day seven post infection, 
irrespective of the genotype and infectious dose. In contrast, increased virus load was found in 
salivary glands from TYK2CD11c and TYK2LysM mice at seven days post infection upon high-dose 
infection, whereas virus was not detectable in TYK2LysM and TYK2/ upon low-dose infection. In 
summary, our data show that TYK2 is required in DCs to control MCMV replication in vitro and 
indicate an organ-specific and infectious dose-dependent contribution of TYK2 in DCs and 
macrophages in MCMV defense in vivo. This study gives insight in which cellular context TYK2 is 
needed to control MCMV infections and may be important to reveal mechanisms of host immunity to 
MCMV infections in greater detail in the future. 
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2. Zusammenfassung 
 
Die Tyrosin-Kinase 2 (TYK2) ist eine der vier rezeptorassoziierten Janus Kinasen (JAKs) der Säugetiere. 
Gemeinsam mit Signal Transduktoren und Aktivatoren der Transkription (STATs) konstituiert TYK2 
den JAK/STAT Signalweg, eine bedeutende, von vielen Zytokinen und Wachstumsfaktoren genutzte, 
Signalroute. TYK2 ist entscheidend bei der angeborenen und adaptiven Immunabwehr gegen Viren 
und andere Pathogene beteiligt. Cytomegaloviren, Mitglieder der Herpesviridae Familie, hatten 
großen evolutionären Erfolg im Umgehen der Immunsyteme ihrer Wirte. Der humane 
Cytomegalovirus (HCMV) ist prävalent in den meisten Populationen weltweit, verursacht einen 
Großteil der infektionsbedingten angeborenen Geburtsdefekte und ist verantwortlich für vermehrte 
Krankheitsanfälligkeit und Sterblichkeit in immunsuppremierten Patienten. TYK2 ist ein bekannter 
Schlüsselfaktor in der Abwehr gegen den murinen Cytomegalovirus (MCMV). Das Ziel dieses Projekts 
ist die Untersuchung zelltypspezifischer Funktionen von TYK2 in der MCMV Abwehr mit speziellem 
Augenmerk auf Dendritischen Zellen (DCs) und Makrophagen. Zu diesem Zweck wurden im Labor 
konditionelle TYK2 Knockout-Mäuse generiert und mit Mäusen gekreuzt, welche das Cre 
Rekombinase Transgen unter der Kontrolle von zelltypspezifischen (z.B. CD11c, LysM) Promotoren 
exprimieren. Gegenstand dieser Diplomarbeit war TYK2CD11c Mäuse hinsichtlich der 
Deletionseffizienz von TYK2 in DCs zu charakterisieren und den Effekt auf die MCMV Abwehr zu 
analysieren. Wir konnten zeigen, dass TYK2 in Knochenmark-DCs (BMDCs) und frisch isolierten Milz-
DCs sehr gut deletiert wird. Ähnlich zu der bereits bekannten Situation in Makrophagen, konnten wir 
auch in DCs von TYK2CD11c und TYK2/entspricht ubiquitärer Deletion von TYK2) Mäusen in vitro 
stark erhöhte MCMV Replikation feststellen. Gemeinsam mit der ebenfalls beobachteten, 
reduzierten Aktivierung von STAT1 und STAT2 reflektiert dies höchstwahrscheinlich eine 
Beeinträchtigung der autokrinen/parakrinen Typ I Interferon (IFN) Signalwirkung. MCMV Infektion in 
vivo führte drei Tage nach der Infektion zu einer erhöhten Virenlast in Lebern von TYK2CD11c Mäusen 
verglichen mit denen von TYK2fl/fl und TYK2LysM Mäusen. Überraschenderweise war dies nur nach der 
Infektion mit niedrigen Infektionsdosen zu beobachten. Sieben Tage nach der Infektion waren die 
Lebern nahezu zur Gänze von Viren befreit, unabhängig vom Genotyp und der Infektionsdosis. Im 
Gegensatz dazu wurde eine erhöhte Virenlast in Speicheldrüsen von TYK2CD11c und TYK2LysM Mäusen 
sieben Tage nach der Infektion mit hoher Infektionsdosis gefunden, wohingegen keine Viren in 
TYK2LysM und TYK2/Mäusen nach Infektion mit niedriger Dosis detektierbar waren. 
Zusammenfassend zeigen unsere Daten, dass TYK2 in DCs benötigt wird um die MCMV Replikation in 
vitro zu kontrollieren. Zudem weisen die Ergebnisse auf eine organ- und infektionsdosisabhängige 
Beteiligung von TYK2 in DCs und Makrophagen an der MCMV Abwehr in vivo hin. Alles in allem, trägt 
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diese Studie zum besseren Verständnis der zellulären Zusammenhänge bei, in denen TYK2 benötigt 
wird, um MCMV Infektionen zu kontrollieren und ist somit ein entscheidender Beitrag zur Aufklärung 
der Abwehrmechanismen gegen MCMV Infektionen. 
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3. Introduction 
3.1. The JAK/STAT Pathway 
 
The Janus kinase (JAK)/signal transducer and activator of transcription(STAT) pathway is an essential 
signal transduction pathway for cytokines and various growth factors1. It basically consists of three 
elements: a transmembrane receptor complex which binds extracellular peptides, JAK proteins which 
are associated at the cytoplasmic tails of the receptor chains, and STAT proteins which are able to 
migrate to the nucleus and induce target gene expression. When ligands bind to the receptor 
complex a conformational change on the cytoplasmic side of the receptor is induced. Due to this 
conformational change associated JAK proteins come in close proximity and get activated by trans- 
and/or autophosphorylation. JAKs then phosphorylate tyrosine residues of the receptor tails and 
therefore create docking sites for STAT proteins. Recruited STAT proteins get phosphorylated by JAKs 
and undergo a conformational change which allows them to dissociate from the receptor. Activated 
STATs then migrate as homo- and/or heterodimers to the nucleus where they bind promoter regions 
of target genes to activate transcription1, 2. 
Four JAKs (JAK1, JAK2, JAK3 and TYK2) and seven STATs (STAT1, STAT2, STAT3, STAT4, STAT5a, 
STAT5b and STAT6) have been identified in mammals3. Although they were initially discovered in 
human cell lines4, the importance of members of the JAK/STAT pathway in vivo was mainly revealed 
by studies using knockout mice. JAK1-/- mice for instance develop neurological lesions causing a 
postnatal lethal failure in suckling5. JAK2 knockouts die on embryonic day 12.5, due to defects in 
definitive erythropoiesis6, 7. Mice lacking JAK3 are viable but display severe defects in lymphoid 
development leading to a severe combined immunodeficiency (SCID-) like phenotype. STAT1 and 
STAT2 knockouts show a dramatically increased susceptibility to infectious diseases due to impaired 
innate immune defense mechanisms. STAT3 is known to regulate cell growth and STAT3-/- mice show 
an early embryonic lethal phenotype. Due to impaired interleukin (IL-) 12 signaling STAT4-/- mice have 
defects in Th1 cell development, while STAT6-/- mice show severely impaired Th2 cell differentiation. 
STAT5a and STAT5b share 96% sequence homology and are to some extend functionally redundant. 
Impaired mammary gland development and lymphohematopoietic defects were reported in 
STAT5a-deficient mice, whereas STAT5b-deficient males are significantly smaller than wild type 
males, express higher levels of female-specific liver genes and show a loss in expression of male-
specific liver genes. Double knockout mice show a combined phenotype with severe defects in 
development and expansion of myeloid and lymphoid cell lineages8. 
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3.2. TYK2 
3.2.1. Structure 
Tyrosine kinase 2 (TYK2) was the first described member of the JAK family of non-receptor tyrosine 
kinases9, 10. It is considered to be ubiquitously expressed although unpublished data from our 
laboratory suggest differences in expression levels between cell types and organs. In humans the 
TYK2 gene is located on chromosome 19 and in mice on chromosome 9. The TYK2 protein is a multi-
domain protein, consists of about 1200 amino acids and shares seven homology regions with all 
other JAKs (JH1-JH7)11, 12. At the C-terminal end the JH1 domain functions as active kinase with the 
catalytic activity located at the so called activation loop around two conserved tyrosine residues. The 
pseudokinase domain (JH2) takes over eminent regulatory functions. Further toward the N-terminal 
end, the src-homology 2 (SH2) domain is located (JH3/4), which until now has no known function. 
The largest domain is a four-point-one, ezrin, radixin, moesin (FERM) homology domain spanning 
JH4, JH5, JH6 and JH7. This domain mediates the interaction and specificity of JAKs with their 
appropriate receptor12. 
 
3.2.2. TYK2 Functions in Signaling 
The function of TYK2 was first analyzed by studies with a TYK2-deficient human fibrosarcoma cell 
line13. Today the B10.Q/J (B10.D1-H2q/SgJ.) mouse strain, carrying a natural mutation in TYK2, and 
three TYK2 knockout mice, which were generated by different groups using different targeting 
strategies, are available to study TYK2 functions14-17.  
TYK2 is associated with different receptor complexes and gets activated by several cytokines (Fig. 1). 
It is localized on the cytoplasmic side of IFN-α/β receptor 1 (IFNAR1) in the type I interferon (IFN) 
receptor complex consisting of IFNAR1/TYK2 and IFNAR2/JAK1. This complex mainly induces STAT1 
and STAT2 activation but, dependent on the cell type, all other STATs can get phosphorylated as 
well18. In human cell lines lacking TYK2 type I IFN signaling is dramatically impaired due to a 
significant reduction of IFNAR1 surface expression19. In contrast, murine TYK2-/- macrophages and 
fibroblasts show normal IFNAR1 levels and just partially impaired IFN-α and IFN-β signaling15, 17.  
Associated with IL-10 receptor 2 (IL-10R2) TYK2 also takes part in IL-10 family signaling. The role of 
TYK2 in most of these pathways has not yet been analyzed but at least for IL-10 signaling a redundant 
function of TYK2 can be suggested as it has been shown that the IL-10 response remains unchanged 
in splenocytes lacking TYK215, 16. Contrarily, in TYK2-deficient macrophages, reduced IL-10 dependent 
STAT3 activation and decreased suppression of IFN-induced nitrite production was observed in a 
different study20. 
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Two members of the IL-12 family, IL-12 and IL-23, signal through the TYK2-associated IL-12Rβ1 in 
combination with JAK2-associated IL-12Rβ2 or IL-23R. Absence of TYK2 in this complex significantly 
impairs IL-12 signaling15, 21, 22. Nevertheless, costimmulatory effects of IL-12 on T-cell proliferation 
remain unchanged16. Reduced IL-23 mediated STAT3 activation has been reported in T-cells derived 
from a mutant TYK2 defective mouse strain14. 
Additionally, TYK2 can be activated by cytokines like IL-6, IL-11, IL-27, leukemia inhibitory factor (LIF), 
oncostatin M (OSM) and ciliary neurotrophic factor (CNTF) which utilize gp130 consisting receptor 
complexes. Signal transduction by this complex is mainly dependent on JAK1. TYK2 was shown to 
have a redundant role in IL-6 and LIF signaling15. TYK2 can also associate with IL-13Rα1 and was 
shown to be needed for the induction of IL-13 target genes in human cells23.  
 
Figure 1: Receptor complexes where TYK2 is associated11 
 
3.2.3. Role of TYK2 in Infectious Diseases 
Most importantly, it has been shown that the absence of TYK2 leads to a significantly higher 
susceptibility to infectious diseases. During Lymphocytic Choriomeningitis Virus (LCMV) infection, for 
example, TYK2-/- mice fail to instigate CD8+ cytotoxic T-cells (CTL), which are important effector cells 
of the adaptive immune system15. TYK2-/- mice show higher virus titers in spleens, lungs, livers and 
salivary glands and increased lethality during murine Cytomegalovirus (MCMV) infection24. 
Furthermore, after intravenous infection of TYK2-deficient mice with Vaccina Virus (VV), increased 
virus titers were detected in the spleens15. Facing protozoan pathogens a higher susceptibility against 
Leishmania major and Toxoplasma gondii due to impaired IFN-γ production in natural killer (NK-) 
cells and T-cells was reported25, 26. TYK2-/- mice infected with the bacterium Listeria monocytogenes 
show increased mortality compared to wild type mice. This might be attributed to impaired dendritic 
cells (DC) priming of CD8+ T-cells and defective T-cell dependent IFN-γ production27, 28. In Escherichia 
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coli infections, TYK2-/- mice showed higher bacterial load and expressed less IL-17 which correlated 
with reduced neutrophile granulocyte numbers in the peritoneal cavity29. 
In summary, the most prominent defects in the immune defense against infectious diseases in TYK2-/- 
mice is the impaired IL-12 mediated IFN-γ production plus, to a less well-defined extend, impaired 
IL-23-mediated IL-17 expression and reduced IFN-α/β responses (Fig. 2). However, TYK2 is activated 
by a number of other cytokines (as outlined above) which are crucial for immune responses or have 
still unknown functions. Future analysis will be required in order to fully understand the many 
functions of TYK2, in particular with respect to cell type and pathogen specificities.  
 
 
Figure 2: TYK2 in infections. Pathogen encounter induces IFN-α/β, IL-12 and IL-18 
secretion of antigen presenting cells (APCs). Upon IFN-α/β (type I IFN) and IL-12 
stimulation NK-cells and T-cells produce and release IFN-γ (type II IFN) in a STAT4- and 
TYK2-dependent manner. Additionally IFN-γ can also be induced by type I IFN in synergy 
with IL-18. IFN-γ propels cytotoxicity of NK-cells and CTLs, inhibits Th2 and Th17 
differentiation and, together with IFN-α/β induces, antiviral and antibacterial actions in 
most cell types. Type I and II IFNs activate macrophages and DCs and, in a positive 
feedback loop, induce production of more IL-12 by these cells. TYK2 is also needed for the 
production of IL-17 by γδ T-cells and most likely also by Th17 cells which can be co-
induced by IL-23 and also require STAT3
11
. 
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3.2.4. TYK2 in Other Diseases 
In inflammatory and autoimmune diseases a lack of TYK2 has been shown to mitigate disease 
phenotypes. TYK2-deficient mice survive high-dose LPS-induced endotoxin shock and are resistant to 
collagen induced arthritis22, 30, 31. TYK2 is also involved in development of experimental autoimmune 
encephalomyelitis (EAE), contributes to intestinal ischemia/reperfusion injury and has been reported 
to worsen collagen-induced arthritis (CIA)22, 32-34. An exception to that is found in contact 
hypersensitivity (CHS), where the disease phenotype is aggravated in TYK2-/- mice35. Although 
impaired IFN-α/β, IL-12 and IL-23 signaling in the absence of TYK2 likely contributes to the observed 
phenotypes, the precise roles of TYK2 in specific inflammatory and autoimmune diseases are still 
largely unknown. 
Furthermore, TYK2 has a role in cancer development and progression. TYK2-/- mice have increased 
susceptibility to lymphoid tumors as a result of impaired tumor immune surveillance by NK/NKT- and 
T-cells36, 37. Recently, enhanced tumor growth and metastasis of 4T1 breast cancer cells in TYK2-/- 
mice was observed38. Tumor cell intrinsic effects of TYK2 seem to be less important as TYK2 
deficiency did not affect Abelson murine leukaemia virus-induced transformation36. However, 
overexpression of TYK2 has been reported in human breast cancer cell lines as well as in prostate 
cancer and squamous cervical carcinomas39-41.  
Moreover, single nucleotide polymorphisms (SNP) in the human TYK2 gene are associated with an 
increased risk of multiple sclerosis, Crohn´s disease, systemic lupus erythematosus, psoriasis and 
type I diabetes and one SNP has been shown to potentially promote tumor formation11.  
Until now there is only one patient with a homozygous TYK2 defieciency known. This patient suffers 
from atopic dermatitis, shows an autosomal recessive hyper IgE-like syndrome and struggles from 
reoccurring infectious diseases42. 
 
3.3. Innate Immunity to Viruses 
3.3.1. Innate Immune System 
The innate immune system is among the first lines of defense when pathogens like parasites, 
bacteria, fungi or viruses invade a host. Its main functions are the recognition and the early battle 
against entering pathogens in addition to the coordination and stimulation of the later acting 
adaptive immune system. To achieve those tasks the innate immune system relies on different sets 
of specialized immune cells, most importantly macrophages, DCs, neutrophils and NK cells43. 
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3.3.2. Virus Recognition 
The detection of invading virus particles mainly depends on the recognition of pathogen-associated 
molecular patterns (PAMPs). PAMPs are special motifs common to pathogens which can be identified 
as foreign by pattern recognition receptors (PRRs). PRRs detecting viral surface proteins and viral 
nucleic acids can be roughly divided into two different receptor systems: membrane associated 
receptors called Toll-like receptors (TLRs) and cytoplasmic receptors. 
Viral genomes and surface glycoproteins are mainly, but not exclusively, recognized by six of the 13 
known mammalian TLRs. TLR9 detects unmethylated CpG motives of viral DNA, TLR3 recognizes 
foreign dsRNA, TLR7 and TLR8 are specialized in perceiving ssRNA whereas TLR2 and TLR4 sense viral 
surface glycoproteins44.  
Cytoplasmic receptors also function as sensors in the antiviral immune response. Prominent 
subgroups are retinoid acid-inducible gene (RIG)-I-like receptors (RLRs) and nucleotide 
oligomerization domain containing (NOD)-like receptors (NLRs). But recently, a lot of novel antiviral 
cytoplasmic receptors were found in diverse protein families45. 
RIG-I and melanoma differentiation-associated gene 5 (MDA-5), members of the subclass of RIG-I-like 
receptors (RLRs), are cytoplasmic RNA helicases and recognize viral RNA46. The molecular signature 
for virus detection via RIG-I was shown to be uncapped 5´-triphosphate RNA, a motif also produced 
by preceding receptor activity of polymerase III in response to a synthetic mimic of an AT-rich 
nucleotide sequence known as poly(dA-dT)47-49. MDA-5 senses web-like RNA structures produced 
during viral life cycle50.  
NOD2 and NACHT-, LRR-, and PYD domains-containing protein 3 (NALP3) belong to the NLRs 
subgroup of cytoplasmic PRRs. NOD2 can drive antiviral host responses by detecting and binding 
single stranded RNA51. In response to Adenovirus and Influenza Virus infection NALP3 has been 
shown to stimulate host inflammatory response52, 53. The same function is carried out by absent in 
melanoma 2 (AIM2) in response to VV and cytosolic DNA54, 55. Another cytoplasmic DNA sensor, 
called DNA-dependent activator of interferons (DAI), has been shown to be crucial in antiviral 
response to synthetic DNA, Herpes Simplex Virus 1 (HSV-1) and human Cytomegalovirus (HCMV)56, 57.  
 
3.3.3. Early Antiviral Host Responses 
In early innate immune response the production and secretion of type I IFNs and proinflammatory 
cytokines are crucial events to fight viral infections. Most PRRs that recognize viruses trigger signal 
transduction cascades leading to the activation of IFN regulatory factor 3 (IRF3) and nuclear factor 
‘kappa-light-chain-enhancer’ of activated B-cells (NF-κB). IRF3 and NF-κB are essential transcription 
factors to drive production and secretion of IFN-β, whereas NF-κB also propels the production of 
-13- 
proinflammatory cytokines like IL-6, IL-1β and tumour necrosis factor alpha (TNF-α). Type II IFN 
(IFN-γ) is produced by NK- and Th-cells and together with type I IFNs upregulate antiviral effector 
molecules that can inhibit different stages of viral life cycle and elicit an antiviral state which allows 
the cells to react more effectively against (re)-entering pathogens. In addition, IFNs can shape innate 
and adaptive immune responses. For example, they promote the activity of NK-cells, DCs, 
macrophages and CTLs58, 59. 
 
3.4. Cytomegalovirus (CMV) 
3.4.1 Introduction 
Cytomegaloviruses belong to the family of Herpesviridae and form the subfamily of 
Betaherpesviridae alongside with the genera Muromegalovirus, Roseolovirus and Proboscivirus60. 
These enveloped dsDNA viruses range among the mammalian viruses with the largest coding 
capacity with genome sizes of about 230 kilo base pairs and more than 200 open reading frames61.  
HCMV is found in all geographic locations and socioeconomic groups. According to recent data 90% 
of all adults are seropositive. Immune suppressed individuals can develop severe diseases like 
pneumonia or encephalitis when infected with CMV. It has also been shown that CMV triggers the 
majority of infection-related congenital birth defects. Furthermore, there is evidence that HCMV is 
involved in vascular diseases and has a role in chronic inflammatory disorders and other human 
malignancies62, 63. CMV can infect several different cell types and tissues but is also known for its high 
degree of species specificity. Therefore, no animal model exists for examining HCMV pathogenesis, 
but similar viruses are found in almost all mammalian species64. Due to the fact, that MCMV infection 
in mice shares many characteristics with HCMV infection in humans, the mouse model is well 
established for studying questions that cannot be addressed in clinical research61.  
 
3.4.2. Experimental MCMV Infection and Early Host Responses 
In nature the primary route of MCMV entering the host is through the epithelium of the 
gastrointestinal and upper respiratory tract, although sexual transmission or a transmission by bite 
are also possible65. In experimental infections MCMV can be administered intraperitoneally, 
subcutaneously, cerebrally or intravenously. MCMV from two different sources is used in research: 
tissue culture-derived virus (TC-MCMV) and salivary gland-derived virus (SG-MCMV). Disease 
manifestation differs depending on the type of virus administered. SG-MCMV is much more virulent 
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in vivo than TC-MCMV when used at equal titers, whereby TC-MCMV is usually asymptomatic in 
immunocompetent mice65. 
Inbred mouse strains differ considerably in their susceptibility to MCMV infection. A major 
determinant of host resistance could be identified as the NK-cell activating receptor Ly49H. Ly49H is 
expressed in the more resistant C57BL/6 mouse strains but is absent in highly susceptible BALB/c 
mice66. The following paragraph discusses studies done by using mice on C57BL/6 background. 
Figure 3 shows the most important host responses in early MCMV defense. Upon intraperitoneal 
infection of C57BL/6 mice, MCMV spreads hematologically and enters various organs. High levels of 
virus replication in spleens and livers with loss of liver function and immunosuppression are the 
primary features of infection65. In the spleen LTβR+ marginal zone stromal cells become infected first, 
which then produce and secrete the first wave of type I IFNs about eight hours after infection. These 
stromal cells require LTα1β2 expressing B-cells to maintain their differentiation state. Most of the 
systemic type I IFNs from this time point until 44-48h post infection are produced in the spleen. At 
the same time type I IFNs and IL-12 are also produced in the liver, but underlying mechanisms and 
responsible cell types are not yet identified. Initial IFN-α/β production in the liver is required to 
recruit CCR2+ macrophages/monocytes, which then also contribute to type I IFN and IL-12 production 
in the liver. In addition those CCR2+ cells together with resident macrophages are considered to be 
important for NK-cell recruitment to the liver. IFN-α/β directly inhibits virus replication and together 
with IL-12 activates immune effector cells, most importantly NK-cells. The first round of replication of 
MCMV lasts 30-36 hours. In spleens, approximatly 36 hours post infection plasmacytoid DCs (pDCs) 
have migrated from the red pulp to the marginal zone and from 36-48 hours post infection produce 
most of splenic and systemic IFN-α/β in a TLR9-dependent manner. At that time point myeloid DCs 
(mDCs) also produce small amounts of IFN-α/β in livers and spleens but in a TLR9-independent 
manner. Interestingly, 44-48h post infection the major contribution to type I IFN production in the 
spleen is switched from pDCs to mDCs. In livers similar effects were described, indicating importance 
of DC- or monocyte-derived IFN-α/β production after 44-48h, but the exact cell type responsible is 
not yet identified. Secretion of IL-12/IL-18 in addition to IFN-α/β by pDCs and mDCs leads to 
stimulation of IFN-γ production by NK/NKT- and T-cells67. IFN-γ in synergy with TNF-α is capable of 
inducing an antiviral state early during MCMV infection and supports T-cell mediated killing of 
infected cells by upregulation of major histocompatibility complex class I (MHC I) at later stages68. 
Whereas Ly49H expressing NK-cells are the main effector cells in controlling MCMV infection for the 
first two days of infection, CD8+ T-cells adopt this regulating function later in infection67.  
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Figure 3: Early innate and adaptive MCMV defenses in the spleen (left, pink) and liver (right, orange). Events 
until 44 hours (<44h) post infection are shown above the dotted line, whereas subsequent events are shown 
below (>44h). 
 
3.4.3. Signaling Cascades in MCMV Infection 
As shown in Figure 4, MCMV is detected by TLR3 and/or TLR9 and there is evidence that also TLR7 
functions redundantly with TLR9 in MCMV infection67, 69. These receptors are all located in the 
endosomes of innate immune cells where many viruses arrive through the endocytic pathway or 
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uptake in apoptotic bodies of previously infected cells70. TLR9 seems to be the most important 
receptor in MCMV response67. Like most other TLRs, TLR9 signaling depends on myeloid 
differentiation primary response gene 88 (MYD88). After binding of unmethylated CpG DNA in 
endosomes, the cytoplasmic domain of the receptor activates MYD88. MYD88 than recruits and 
phosphorylates IL-1 receptor associated kinase (IRAK) which interacts with TNF receptor associated 
factor 6 (TRAF6). Via the IKK complex IRAK is able to activate NF-κB. NF-κB drives IFN-β and 
proinflammatory cytokine production whereas IRF7, an IFN-inducible factor, which is constitutively 
expressed in pDCs and also gets activated through IRAK71, is needed for the upregulation of most 
IFN-α subtypes72. 
In addition, TLR3 is able to recognize MCMV. Upon ligand binding, TLR3 gets phosphorylated on its 
cytoplasmic tail and recruits TIR domain-containing adaptor inducing IFN-β (TRIF)73, 74. Via receptor 
interacting protein (RIP) TRIF then activates the IKK complex, which further on leads to the 
phosphorylation and degradation of an NF-κB inhibitory protein. Released NF-κB translocates into 
the nucleus and among others binds the IFN-β promoter region to activate transcription. TRIF can 
additionally signal through the TANK-binding kinase 1 (TBK1) complex. IRF3 molecules become 
phosphorylated dimerize and like NF-κB translocate to the nucleus to stimulate IFN-β production75. 
Secreted type I IFNs function in an autocrine and paracrine manner and activate the JAK/STAT 
pathway, which was already schematically described in chapter “3.1. The JAK/STAT Pathway”. In 
response to IFN-a/β mainly STAT1/2 heterodimers are activated and associate with IRF9. 
STAT1/STAT2/IRF9 complexes then activate IFN stimulated genes (ISGs) by binding so-called IFN 
stimulated response elements (ISREs). STAT1 homodimers on the other hand bind preferentially to 
IFN-γ activated site (GAS) elements76, 77.  
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Figure 4: Signaling cascades activated in response to MCMV infection 
 
3.4.4. Innate Immune System Evasion Strategies of MCMV 
From the evolutionary perspective, viruses are in constant battle with their host´s immune systems. 
In order to survive and replicate in a host, viruses have developed a variety of evasion strategies to 
overcome different immune responses. These strategies can be roughly divided in three major 
mechanisms78: 
The first effective strategy to evade the immune response is to avoid detection by immune cells. This 
can be achieved for example by changing immunodominant epitopes on the surface of the virus 
particle. MCMV also uses this strategy since m157, a surface glycoprotein of MCMV, which is 
detected by Ly49H receptors of NK-cells, mutates during infection and therefore lowers the affinity 
to these receptors79, 80 . The second successful strategy to evade the immune system is to directly 
interfere with immune responses to infected cells. The MCMV proteins m06 and m152 are able to 
inhibit major MHC I expression on the cell surface of infected cells and therefore prevent antigen 
presentation to CD8+ CTLs81. The third immune evasion strategy of viruses targets effector functions 
of immune cells like IFN-α/β signaling. This mechanism can be found in MCMV, as the protein m27 is 
able to mediate STAT2 degradation and therefore blocks IFN type I and partially IFN type II 
signaling82, 83.  
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Due to these and many other immune evasion strategies, the immune system is not capable to clear 
MCMV infections entirely. Therefore, like for all Herpesviridae, MCMV infection leads to a lifelong 
latent infection. During the latent phase MCMV genomes but no infectious particles can be detected. 
Reactivation of the virus and resulting reoccurrence of the disease is frequently seen when the hosts 
immune system is affected, for instance by immunosuppression, or as a result of an additional 
infection84. 
 
3.5. Conditional Knockouts 
3.5.1. The cre/loxP System 
The cre/loxP system is a genetic tool to target and remove pieces of DNA in a living organism. Key 
enzyme is the cre recombinase (cre) which is able to recombine two loxP sites in proximity. Adapted 
to every model organism, it has huge fields of application. In mice for instance, the cre/loxP system is 
used to create conditional knockouts when a complete knockout of a specific gene is not viable or to 
express/delete a gene tissue or cell-type specifically. In the latter case the cre gene is controlled by 
an inducible or tissue/cell-type specific promoter. When the promoter is active, cre protein is 
produced and cuts out the floxed (i.e. region flanked by loxP sites) target sequence of the    
genome85, 86. 
 
3.5.2. Conditional TYK2 Knockout Mice 
By using the cre/loxP system, conditional TYK2 knockout mice (TYK2fl/fl) have been created in our 
laboratory [Vielnascher et al., unpublished]. Two loxP sites were inserted in the mouse genome, 
flanking exon 3 of the TYK2 gene, which contains the start codon for translation (ATG)16. In order to 
study cell type-specific functions of TYK2, TYK2fl/fl mice have been crossed to mouse lines expressing 
cre under the control of the cell type-specific promoters of the CD11c87, LysM88, Lck89 and CMV90 
genes (Fig. 5 for CD11c). CD11c is highly expressed on DCs, and to a lower extent, also on 
macrophages, monocytes and neutrophils. By using the LysM promoter to control cre expression 
TYK2 is deleted in cells of the myeloid cell lineage (macrophages, granulocytes, neutrophils), whereas 
Lck/cre targets T-lymphocytes. The CMV promoter is active in all cell types and this conditional 
knockout system is used as a control, mimicking the situation in conventional TYK2 knockout mice. 
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Figure 5: Strategy for cell type-specific deletion of TYK2 on the example of CD11c+ cells 
 
3.6. Dendritic Cells in Immunity 
3.6.1. General Features 
DCs are bone marrow-derived lymphocytes and can be found in surface epithelia like the skin, all 
lymphoid tissues, mucosal epithelium and organ parenchyma. Morphologically most noticeable are 
the membranous projections or dendrites which give those cells their name. DCs act as sentinels, 
which capture pathogens on the periphery, process them, migrate to lymph nodes and present 
antigenic peptides of the degraded pathogens to lymphocytes. Resting DCs in peripheral organs are 
called immature DCs which get activated by uptake of pathogens. The following maturation steps 
involve morphological changes, redistribution of MHC molecules from intracellular endocytic 
compartments to the cell surface, down-regulation of antigen internalization, an increase in the 
surface expression of co-stimulatory molecules, secretion of chemokines, cytokines and proteases, 
and surface expression of adhesion molecules and chemokine receptors91, 92. DCs are able to interact 
with B-cells causing the modulation of B-cell proliferation and differentiation program to become 
plasma cell93, 94. Furthermore, to regulate the humoral response, it has been reported that DCs 
deliver signals for isotype class switching of antibody producing plasma B-cells95. DCs are able to 
activate naïve NK-cells and also play a major role in early cytokine production in response to 
infections96, 97. Another property of DCs is the cross-presentation of antigen. Thereby exogenous 
antigens can be presented attached to MHC class I to directly activate CD8+ CTLs98. But DCs also 
-20- 
participate in establishing tolerance to self antigen by deleting self reacting lymphoid cells in central 
lymphoid organs in order to prevent autoimmune responses99, 100. Taken together DCs have multiple 
important functions in immune response and act as key players in linking innate and adaptive 
immunity. Therefore, DCs are an exciting field of research and are gaining more and more interest by 
immunological researchers. 
 
3.6.2. Subsets of Dendritic Cells 
Different subsets of DCs have been described and can be characterized based on tissue distribution, 
cell surface markers and general functions. Lymphoid tissue DCs are most commonly divided in 
myeloid (mDCs) (also called conventional DCs (cDCs)) and pDCs. mDCs can be further subclassified in 
migratory and lymphoid tissue-resident mDCs101. In contrast to mDCs, pDCs look more like plasma 
cells morphologically and are usually just seen upon pathogen encounter. Both cell types have 
different surface markers and distinct functions in immunity. pDCs express B220 which was originally 
described as a pro-B cell marker and the classical DC cell marker CD11c at low levels whereas mDCs 
show high expression levels of CD11c and no B220 protein on the cell surface102, 103. The different 
subsets of DCs also play individual roles when it comes to their function in innate immune response. 
pDCs constantly express IRF7 and therefore are the first to react against viral infections by producing 
IFN-α via the TLR7/9 pathway. Because of that feature pDCs were formerly also referred as IFN 
producing cells (IPCs)104, 105. mDCs on the other hand are more specialized in antigen presentation 
and TLR3 mediated IFN-β response67, 101, 106.  
 
3.7. Questions and Objectives 
 
Our lab showed previously that TYK2 deficiency in mice leads to higher susceptibility to MCMV 
infection24. Data gained from in vitro cultures revealed a surprisingly strong impact of 
autocrine/paracrine IFN signaling in macrophages upon MCMV challenge. This effect was expected to 
be even more striking in DCs, as they, contrarily to macrophages, were described as important IFN 
producers in early MCMV response67. Therefore, we wanted to investigate the responses of DCs in 
MCMV infection analogous to the studies done in macrophages. In addition, benefiting from the 
availability of conditional knockout mice with TYK2 deletion either in macrophages (TYK2ΔLysM) or DCs 
(TYK2ΔCD11c), we wanted to analyze the in vivo consequences of TYK2 deficiency in MCMV infection. 
This work is part of a combined effort with Michael Rammerstofer to analyze cell type-specific 
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functions of TYK2 in macrophages and DCs. Specific questions to be addressed in this diploma thesis 
are:  
 
1) How efficient is the TYK2 deletion in DCs derived from TYK2ΔCD11c mice? 
 
For further investigation of TYK2-specific functions in DCs we at first wanted to determine the TYK2 
deletion efficiency in TYK2ΔCD11c DCs. A cell culture to grow bone marrow-derived DCs (BMDCs) in 
vitro had to be established in our laboratory to compare TYK2 expression of TYK2fl/fl, TYK2ΔCD11c and 
TYK2Δ/Δ DCs on mRNA and protein level. In addition, splenic DCs should be isolated to quantify the 
TYK2 mRNA expression of CD11c+ cells in vivo. 
 
2) Are TYK2ΔCD11c BMDCs more permissive to MCMV infection and is the autocrine/paracrine 
STAT1/2 activation affected in TYK2ΔCD11c BMDCs? 
 
Previous data showed that MCMV replicates to higher titers in TYK2-deficient bone marrow-derived 
macrophages24. Using a similar approach, the importance of TYK2 in BMDCs in controlling MCMV 
infections had to be analyzed. As shown in macrophages, resistance against MCMV depends on the 
presence of functional IFN-α/β signaling and the presence of STAT1. Therefore the phosphorylation 
status of STAT1 and STAT2 in BMDCs from the respective mice infected with MCMV had to be 
analyzed. 
 
3) What are the consequences of TYK2 deletion in DCs or macrophages in vivo during MCMV 
infection? 
 
Previous data showed higher MCMV titers in organs of infected TYK2-/- as compared to wild type 
mice24. Infection of TYK2ΔCD11c and TYK2ΔLysM mice with MCMV would give insight to the contribution 
of DCs and macrophages to the observed phenotype. To this end, viral load in livers, spleens, salivary 
glands and lungs of infected animals had to be determined. TYK2ΔLck mice were used as a control, 
since T-cell contribution in early immune response should be negligible. This part of the study was 
performed together with Michael Rammerstorfer, who did the in vivo infections of mice and 
determined virus titers of spleens, salivary glands and lungs. Focus of the presented diploma thesis 
was on DCs and MCMV titers in livers. 
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4. Materials and Methods 
4.1. Reagents 
 
Materials Company Code/Cat.No. 
Bio-Rad Protein Dye BioRad, Hercules, CA 5000006 
Bovine Serum Albumin (BSA) Roth Lactan, Graz, Austria T844.3 
Dulbecco´s Modified Eagle Medium (DMEM) PAA Laboratories GmbH, Pasching, Austria E15-843 
ECL Solution GE Healthcare, Munich, Germany RPN2106 
Fetal Calf Serum (FCS) Invitrogen/Gibco, Lofer, Austria 10270-106 
Hank´s Balanced Salt Solution (HBSS) Invitrogen, Lofer, Austria 14175129 
iScript cDNA synthesis kit BioRad, Hercules, CA 170-8890 
L-Glutamine 200mM PAA Laboratories GmbH, Pasching, Austria M11-004 
Low Melting Agarose f. PFA Biozym, Oldendorf, Germany 840100 
Magnetic Cell Sorting (MACS) Buffer Miltenyi Biotech, Bergisch Gladbach, Germany 130091221 
MACS CD11c MicroBeads (N418) Miltenyi Biotech, Bergisch Gladbach, Germany 130052001 
PageRuler Protein Ladder Fermentas, St. Leon-Rot, Germany 26617 
Phosphate Buffered Saline (PBS)  Sigma, St. Louis, MO D8537 
Pen/Strep (100x) PAA Laboratories GmbH, Pasching, Austria P11-010 
peqGOLD TRIFAST peqLab, Erlangen, Germany 30-2020 
ProteinA Sepharose CL-4B GE Healthcare, Munich, Germany 17-0780-01 
Rat Serum Roth Lactan, Graz, Austria S7648 
Red Blood Cell Lysis Buffer Sigma, St. Louis, MO R7757 
SigmaFast Protease Inhibitors Sigma, St. Louis, MO S8820 
Trypsin-EDTA (1:250) PAA Laboratories GmbH, Pasching, Austria L11-004 
 
Standard reagents are not listed and were ordered from Sigma (St. Louis, MO) or Merck (Darmstadt, GER). 
 
4.2. Mice 
 
All mice were on C57BL/6 background. Conditional TYK2 mice have been generated in our lab (see 
Figure 5 or 6). CD11c/cre (B6.Cg-Tg(CD11c-Cre)) mice were described previously87 and crossed with 
TYK2fl/fl (B6.129P2-TYK2fl1BIAT) mice to generate TYK2ΔCD11c mice. Similarly LysM/cre (B6.129P2-
Lyz2tm1(cre)Ifo/j)88, Lck/cre (B6.129P2-Tg(LckCre)89 and CMV/cre (B6.c-Tg(CMV-Cre)Cgn/j)90 mice 
were crossed with TYK2fl/fl mice to generate TYK2ΔLysM, TYK2ΔLck and TYK2ΔCMV mice. In case of TYK2ΔCMV 
mice, the cre recombinase transgene was crossed out again. All mice were housed under specific 
pathogen-free conditions according to FELASA guidelines. Animal experiments were discussed and 
approved by the institutional ethics committee and are conform to Austrian laws (BM.W_Fa ref. 
68.205/0204-C/GT/2007 and ref. 68.205/0233-II/10b/2009). 
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Figure 6: Generation of conditional TYK2 knockout (TYK2fl/fl) mice. Genomic organisation of the TYK2 locus is 
shown from exon 1 to 9 (indicated as black boxes). The targeting vector consists of two homologous arms 
(indicated in red) and the floxed sequence (exon 3 with flanking loxP sites). A floxed neomycin resistance 
cassette (neo
r
, blue box) is located 3´of exon 3 and a thymidine kinase (TK) cassette (grey box) 5´ of the 
construct. The conditional TYK2 allele shows the genomic organisation after homologous recombination and 
deletion of the neomycin resistance cassette. After cre recombination the allele is deficient for exon 3 and 
hence lacks the transcriptional start site. LoxP sites are represented as blue triangles. 
 
4.3. Cell Culture 
 
If not stated otherwise, “Heraeus Multifuge 1S” centrifuge was used for all cell culture methods. 
4.3.1. Murine Embryonal Fibroblasts (MEFs) 
 
MEF Medium 
DMEM (high glucose 4.5g/l) 
10% FCS (heat-inactivated) 
Pen/Strep (100µg/ml and 100U/ml) 
 
PBS + Pen/Strep (50µg/ml and 50U/ml) 
  
 
50µM 2-mercaptoethanol 
2mM L-Glutamine 
 
Isolation and Passaging of MEFs for Experiments 
Embryos on day 13.5 of gestation were dissected from the uterus. The embryos were collected in PBS 
+ Pen/Strep containing petri dishes. Livers and heads of the embryos were removed, the embryos 
were minced with scissors and forceps and pipetted through Pasteur pipettes in MEF medium. The 
suspension was passed through a 100µm cell strainer and centrifuged for 5min at 1000rpm, cells 
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were washed twice with PBS, resuspended in MEF medium and seeded into two 10cm cell culture 
plates/embryo. Next day the cells were washed with PBS twice. On day 3-4, when cells reached near 
confluency, cells were either frozen or expanded for experiments. 
For passaging, MEFs were washed with PBS once, 1.5 ml of Trypsin-EDTA (1:250) was added per 
10cm plate and dissociation of cells was observed via microscope. Trypsin reaction was stopped by 
adding 3ml MEF medium per 10cm plate. Cells were resuspended in medium and centrifuged at 
1000rpm for 5min. The pellet was resuspended in 5ml MEF medium and cells were seeded on new 
plates at the desired dilution. For experiments the cell number was determined using a Neubauer 
counting chamber. For plaque forming assays 2x104 cells were plated per well of a 24 well plate. 
 
4.3.2. Bone Marrow-Derived Macrophages (BMMΦs) 
L929 Cell Conditioned Medium 
L929 cells were described previously 
107
. The cells were grown on 15cm cell culture dishes in MEF medium to 
approximately 70% confluency. Medium was removed and 30ml DMEM (+Pen/Strep, +L-Glutamine) were 
added. The plates were incubated for 10 days at 37°C before the supernatant was collected and sterile 
filtrated. Aliquots of L929 cell conditioned medium were stored at -20°C. 
 
BMMΦ Medium 
DMEM (high glucose 4.5g/l) 
10% FCS (heat-inactivated) 
Pen/Strep (100µg/ml and 100U/ml) 
2mM L-Glutamine 
50µM 2-mercaptoethanol 
15% L929 conditioned medium (CM) 
 
 
 
 
 
1x Schindler Buffer  
50mM Tris/HCl pH8 
150mM NaCl 
0.5% NP40 (IPEGAL) 
10% Glycerol 
2mM DTT 
0.1mM EDTA  
0.2mM Na-Vanadate  
25mM Na-fluoride 
1x SigmaFast protease inhibitors 
1mM PMSF 
 
Isolation, Passaging and Harvesting of BMMΦs 
Mice at the age of 8 to 12 weeks were sacrificed by cervical dislocation and tibia and femur were 
prepared. Under sterile conditions the bones were cut on both ends and bone marrow was flushed 
with 5ml medium into petri dishes. Cells were resuspended and plated on four 10cm petri dishes per 
mouse adding BMMΦ medium to a total of 12ml per plate. After 3 days medium was changed. To 
split BMMΦs (usually on day five after isolation) the cells were washed with 5ml PBS. Then cells were 
scraped in 5ml BMMΦ medium using a silicon scraper and were resuspended thoroughly. The cells 
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were split depending on their density and supplied with 12ml BMMΦ medium per 10cm plate. When 
plated for experiments (day 6) the cell count was determined using a Neubauer counting chamber. 
1.5x106 cells per well (6-well tissue culture plate) were seeded in 3ml BMMΦ medium and incubated 
over night at 37°C.  
To harvest whole cell extracts, cells were washed twice with ice cold PBS, 100µl 1x Schindler buffer 
per well (6-well plate) were added and cells were scraped off using silicon scrapers. Cell lysates were 
kept on ice for 30min. To remove cell debris, samples were centrifuged (5000rpm [Eppendorf 
Centrifuge 5415r], 2min, 4°C), supernatant was transferred to new tube and stored at -80°C.  
 
4.3.3. Bone Marrow-Derived Dendritic Cells (BMDCs) 
X63 Conditioned Medium 
Cells of the mouse myeloma cell line X63 (kind gift of Volker Thiel, Basel), producing GM-CSF, were grown in 
cell culture flasks in DMEM supplemented with 10% FCS, Pen/Strep (100µg/ml and 100u/ml) and 2mM L-
Glutamine. The cells were split 1:3 (usually every 2-3 days) by rinsing from the bottom of the flasks and 
transferring to a new flask before adding medium. For the production of X63 conditioned medium cells were 
incubated at 37°C for 10 days when they were very dense. The medium was taken off and sterile filtrated. 
Aliquots of X63 conditioned medium (6-8ml) were stored at -20°C to avoid freeze/thaw cycles. 
 
BMDC Medium 
DMEM (high glucose 4.5g/l) 
10% FCS (heat-inactivated) 
Pen/Strep (100µg/ml and 100U/ml) 
2mM L-Glutamine 
10% X63 conditioned medium (added right before use) 
 
Isolation, Passaging and Harvesting of BMDCs 
Mice at the age of 8 to 10 weeks were sacrificed. Femur and tibia of mice were isolated and bone 
marrow was flushed with 5ml MEF medium into non-cell culture plates. The cells were suspended by 
pipetting up and down several times and centrifuged at 1000rpm for 5min. The pellet was 
resuspended in 1ml red blood cell lysis buffer and incubated for 1min under constant shaking. The 
lysis was stopped by adding 3ml MEF medium. The suspension was centrifuged at 1000rpm for 5min 
and the pellet was resuspended in BMDC medium. 107 cells were plated in 5ml BMDC medium per 
10cm non-cell culture plate. On day 3 after isolation 5ml BMDC medium containing 10% X63 
conditioned medium was added per plate. 
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For experiments, BMDCs were transferred onto cell culture plates on day six after isolation. The cells 
were scraped off using silicon scrapers and collected by centrifugation (1000rpm for 5min). The pellet 
was resuspended in 5ml BMDC medium and the cells were counted. For Western blot and RNA 
isolation 107 BMDCs were seeded on 10cm cell culture plates in 10ml BMDC medium. For infection 
experiments with MCMV 5x105 cells in 500µl BMDC medium were plated per well at 24 well plates. 
On day 8 after isolation BMDCs were scraped off the bottom of the 10cm plates and transferred to 
tubes. The cells were collected by centrifugation at 1000rpm for 5min. For RNA isolation pellets were 
resuspended in 1ml TriFast and stored at -80°C. For protein isolation the cells were resuspended in 
1ml 1x Schindler buffer and incubated on ice for 30min. Cell debris was removed by centrifugation at 
5000rpm [Eppendorf Centrifuge 5415r] for 2min at 4°C. Samples were stored at -80°C. 
 
Infection of BMDCs with MCMV 
BMDCs were infected in 24 well plates with TC-MCMV at an MOI of 5. For infection 250µl of the 
500µl medium in every well were taken off and 250µl medium containing MCMV were added. The 
plates were centrifuged at 800rpm for 30min and then incubated for one hour at 37°C. The infection 
medium was taken off and the wells were washed with PBS. 500µl fresh BMDC medium was added 
and the plates were incubated at 37°C for the times needed. 
To harvest MCMV infected BMDCs for the virus replication experiment the plates were sealed with 
parafilm and stored at -80°C. After thawing, lysed cells were harvested pipetting up and down and 
the samples were directly used for plaque forming assays. To harvest protein lysates of MCMV 
infected BMDCs the cells were scraped off the bottom of the well and the suspension was 
transferred to eppendorf tubes. The cells were collected by spinning them down at 5000rpm for 
5min, lysed in 50µl 1x Schindler buffer and incubated on ice for 30min. Cell debris was removed by 
centrifugation at 5000rpm [Eppendorf Centrifuge 5415r] for 2min at 4°C, before storing at -80°C. 
 
4.4. Murine Cytomegalovirus (MCMV) 
 
Sucrose/Virus Standard Buffer (VSB) 
50mM Tris/HCl, pH7.8 
12mM KCl 
5mM Na2EDTA 
15% w/v sucrose 
Reagents were mixed and sterile filtrated through a 0.2µm filter. VSB can be stored up to 8 months at 4°C. 
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Agar for Plaque Forming Assays (PFA) 
4% low melting agarose was suspended in PBS, autoclaved and stored at RT. Before use agarose was 
melted in a microwave and incubated for 10min at 37°C to cool down. Three parts of MEF medium at 
37°C were mixed with one part of 4% agarose and used immediately to overlay cells.  
 
TC-MCMV Growth and Purification 
TC-MCMV was propagated in C57BL/6 MEFs. MEFs were grown in complete MEF medium in 15cm 
cell culture plates to 70-80% confluency and infected with TC-MCMV (MOI=0.01). Plates were rocked 
every 30min for 2 hours to ensure equal infection. 20ml complete MEF medium was added and 
plates were incubated at 37°C. On day 4-5 post infection (complete cytopathic effect visible) MEFs 
and supernatants were collected and frozen at -80°C in 50ml Falcon tubes. By using dry ice at least 3 
freeze/thaw cycles were performed to ensure complete lysis of cells. Virus suspension was 
centrifuged at 6000rpm [Beckman Avanti J-25, Rotor JA25/50] for 20min at 4°C. The supernatant was 
kept on ice while the pellet was dounced 20 times (Wheaton tight fitting tissue grinder) on ice and 
centrifuged at 12000rpm [Beckman Avanti J-25, Rotor JA25/50] for 10min at 4°C. The pellet was 
discarded. Both supernatants were pooled and centrifuged at 14000rpm [Beckman Avanti J-25, Rotor 
JA25/50] for 3.5 hours at 4°C in JA-25 tubes to pellet TC-MCMV particles. The supernatant was 
removed and the pellets were resuspended in medium and incubated on ice over night. Next day the 
TC-MCMV suspension was dounced 20 times on ice and carefully pipeted on a 25ml VSB cushion in 
ultra centrifuge SW-28 tubes. After centrifugation with 25000rpm [Sorvall Ultra Pro 80] for two hours 
at 4°C, supernatants were discarded, the pellets were overlaid with VSB and incubated on ice over 
night. Next day the virus pellet was resuspended, dounced 80-100 times on ice and passed through a 
0.45µm sterile filter to get rid of multicapsids and virus aggregates. Virus aliquots were stored at 
-80°C. 
 
Homogenization of Livers of MCMV-Infected Mice 
Mice infected with TC-MCMV were sacrificed by cervical dislocation and livers were dissected. Single 
cell suspensions were prepared by mashing livers through 100µm cell strainers. To release virus 
particles from liver cells they were dounced in 2ml PBS using a tissue grinder (Wheaton tight fitting). 
Every liver was dounced 20 times and aliquots were stored at -80°C. 
 
Plaque Forming Assay (PFA) 
MEFs were grown to 50-60% confluency in 24 well cell culture plates (Falcon). After the medium was 
taken off cells were infected with 500µl virus inoculum. Plates were centrifuged with 800rpm 
[Heraeus Multifuge 1S] for 30min and incubated at 37°C for two hours. To ensure proper MCMV 
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distribution plates were rocked every 20 minutes while incubating. After incubation the inoculum 
was removed and cells were overlaid with agar-medium. Plates were kept at room temperature until 
agar was hardened and then incubated at 37°C for 4-5 days before counting plaques. 
 
4.5. Immunoprecipitation(IP) / SDS-PAGE / Western Blot 
 
ProteinA-Sepharose Beads 
Freeze-dried ProteinA-Sepharose was washed four times with sterile water and then twice with 20% ethanol. 
ProteinA-Sepharose beads were stored in 20% ethanol at 4°C.  
 
Antibody Solutions 
Primary antibodies were diluted 1:1000 in 1% BSA in PY-TBST. To prevent contamination 0.01% Na-Azide was 
added to primary antibody solution. Secondary antibodies were diluted 1:2000-1:4000 in 1% BSA in PY-TBST 
without adding Na-Azide.  
 
1x Transfer Buffer 
25mM Tris/HCl 
150mM Glycine 
20% Methanol 
 
1x Running Buffer 
192mM Glycine 
25mM Tris/HCl pH 7.4 
0.1% SDS 
 
2x Lämmli Sample Buffer (LSB) 
126mM Tris/HCl pH 6.8 
4% SDS 
20% Glycerine 
200mM DTT 
0.02% Bromphenol Blue 
 
PY-TBST 
10mM Tris/HCl pH7.4 
75mM NaCl 
1mM EDTA pH8 
0.1% Tween20 
Stacking Gel 
5% Acrylamid/Bisacrylamid 
126mM Tris/HCl pH 6.8 
0.1% SDS 
0.06% APS 
0.07% TEMED 
 
Separation Gel  
6,5% Acrylamid/Bisacrylamid 
375mM Tris/HCl pH 8.8 
0.1% SDS 
0.075% APS 
0.09% TEMED 
 
Strip Buffer 
2M Glycine/HCl pH 2.5 
0.25% SDS 
 
Blocking Solution  
5% milk powder in 1x PY-TBST 
 
.
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Immunoprecipitation 
Protein concentration of whole cell extracts was determined using Bio-Rad Protein Dye according to 
manufacturer’s instructions. 1mg protein in 1ml 1x Schindler buffer was mixed with either 4µg TYK2 
antibody or 2µg JAK1 antibody and incubated rotating over night at 4°C. Next day 50µl 
protein-sepharose slurry (washed 3 times in 1x Schindler buffer and resuspended to ~50% v/v slurry 
prior to use) was added to each sample. After rotating at 4°C for two hours the samples were 
pelleted (13000rpm [Eppendorf Centrifuge 5415r], 20sec, 4°C) and washed with 1x Schindler buffer 3 
times. Then the pellets were resuspended in 50µl 2x LSB and stored at -20°C. Prior to loading on SDS-
PAGE gels, the samples were heated at 96°C for 10min and centrifuged for 2min at 12000rpm 
[Eppendorf Centrifuge 5415r] and 4°C. 20µl-25µl of the supernatants were loaded. 
 
SDS-PAGE and Western blot 
For SDS-PAGE 10-20µg protein extract were loaded per lane and Page Ruler (Fermentas) was used as 
molecular weight standard. Electrophoresis was run for 1.5-2 hours on 100V in 1x running buffer. 
After proteins were separated by SDS-PAGE the proteins were blotted on nitrocellulose membranes 
by semidry blot (1mA/cm2 of membrane; 2h). The membrane was rinsed in PY-TBST and incubated 
with blocking solution for 1h. Then the membrane was washed 3 times in PY-TBST and incubated 
with primary antibody over night at 4°C. The membrane was washed 3 times and incubated with the 
secondary antibody for 1h. After another washing step (3 times) the membrane was incubated with 
ECL solution for 1min and exposed to a light sensitive film. Membranes were stripped by incubating 
in strip buffer for 2 hours. Then the membrane was washed with hot water before it was reblocked in 
blocking solution and used for reprobing.  
 
Antibodies Source Company Code/Cat.No. 
anti-mouse IgG sheep  GE Healthcare, Munich, Germany NA9310 
anti-rabbit IgG donkey  GE Healthcare, Munich, Germany NA9340 
anti-phospho-STAT1 (Tyr701) rabbit  Cell Signaling, Danvers, MA 9167 
anti-STAT1 rabbit  Cell Signaling, Danvers, MA 9172 
anti-phospho-STAT2 (Tyr689) rabbit  Millipore, Billerica, MA 07-224 
anti-STAT2 rabbit  Santa Cruz Biotechnology, Santa Cruz, CA sc-839 
anti-phospho-STAT5 (Tyr694) mouse Cell Signaling, Danvers, MA 9356 
anti-STAT5 rabbit  Santa Cruz Biotechnology, Santa Cruz, CA sc-835 
anti-JAK1 rabbit  Santa Cruz Biotechnology, Santa Cruz, CA sc-277 
anti-TYK2 rabbit  piCHEM, Graz, Austria, custom made  -------- 
anti-panERK mouse BD Biosciences 610124 
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4.6. RNA Isolation / cDNA Synthesis / Quantitative PCR (qPCR) 
 
DEPC-H2O 
0.01% DEPC in sterile water were incubated over night and autoclaved next day. 
 
RNA Isolation and cDNA Synthesis 
“Eppendorf Centrifuge 5415r” centrifuge was used for RNA isolation. Cells were lysed in 1ml 
peqGOLD Trifast. Samples were stored at -80°C or were used directly for RNA isolation after 5min 
incubation at room temperature. 0.2vol chloroform was added per sample and after shaking for 
15sec the samples were incubated at room temperature for 2-3min. Following centrifugation at 
12000rpm for 15min the clear upper aqueous phase was transferred to a new eppendorf tube and 
1vol isopropanol was added. The samples were incubated for 10min at room temperature and then 
centrifuged at 12000rpm for 10min on 4°C. The supernatant was removed and the pellet was washed 
once with 75% ethanol. After pelleting (5min, 7500rpm, 4°C) the supernatant was removed and the 
RNA pellet was dried at 60°C. The pellet was resuspended in DEPC-H2O and incubated on ice for 
30min. To dissolve properly the samples were heated to 56°C for 30min and pipeted up and down 
several times. RNA in DEPC-H2O was stored at -80°C or used directly for cDNA synthesis. The 
concentration of isolated RNA was determined using 4µl sample in 96µl TE buffer (OD260/OD280) and 
the RNA integrity was checked on agarose gels. Then total RNA was reverse transcribed using iScript 
cDNA synthesis kit. 
 
Quantitative PCR (qPCR) 
The following concentrations were used for qPCR analysis: 
 
MgCl2 (25mM) 4 mM 
Primer fw (10 pmol/µl) 300 nM 
Primer rev (10 pmol/µl) 300 nM 
Probe (10 pmol/µl) 100 nM 
HotfirePol (5 U/µl) 1 U/rxn 
dNTP mix (2mM each) 200 µM 
10x Hotfire B buffer 1x 
Template (cDNA) 2µl* 
 
* cDNA equivalent to 1µg of reverse transcribed RNA 
 
The primers for the TYK2 qPCR reaction were designed to bind in the deleted region of exon 3, 
excluding signals from truncated TKY2 mRNA present in TYK2ΔCD11c BMDC. Ube2d2 was used as 
endogenous reference gene. 
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Primer and Probes Sequence 
Ube2d2 fw:  5´-AGGTCCTGTTGGAGATGATATGTT-3´ 
Ube2d2 rev: 5´-TTGGGAAATGAATTGTCAAGAAA-3´ 
Ube2d2 TaqMan Probe:  5´-CCAAATGACAGCCCCTATCAGGGTGG-3´ 
TYK2
fl/fl 
fw: 5´-GGGTCACCTTCAGCCAGACA-3´ 
TYK2
fl/fl 
rev: 5´-GACCTTAGCCTGTGCATTGTAGAGT-3´ 
TYK2
fl/fl 
TaqMan Probe: 5´-CACATCGCACACAAAGTCGGCATCA-3´ 
 
Samples were analyzed in duplicates using Eppendorf Real Plex cycler.  
Cycling conditions: 15 min at 95°C then 45 cycles of 20 sec, 95°C and 1 min, 60°C 
 
Fluorescence data were collected during the extension phase (step 3). Target gene expression was 
calculated by normalizing cycle threshold (Ct) values to endogenous control (Ube2d2) and were 
shown relative to unstimulated wild type samples. 
 
4.7. Magnetic Cell Sorting (MACS) 
 
Isolated spleens were passed through 100µm cell strainers under sterile conditions. Splenocytes 
were homogenized in 5ml MEF medium and centrifuged for 5min at 1000rpm [Heraeus Multifuge 
1S]. The pellet was resuspended in 1ml red blood cell lysis buffer and incubated under constant 
shaking for 2min. The lysis was stopped by adding 3ml MEF medium. After centrifugation at 1000rpm 
[Heraeus Multifuge 1S] for 5min the pellet was resuspened in MEF medium first and after a second 
centrifugation step in 900µl MACS buffer. 100µl MACS beads (CD11c) were added. The suspension 
was incubated for 20min at 4°C and shaken occasionally to ensure proper binding of MACS beads. 
Then 4ml MACS buffer were added, the sample was centrifuged as above and the supernatant was 
discarded. The pellet was resuspended in 1ml MACS buffer and pipeted on an MACS column. The 
column was rinsed twice with 500µl MACS buffer. After removing columns from the magnetic field, 
positively selected cells were eluted with 1ml MACS buffer and either used directly for FACS analysis 
or RNA isolation. 
 
4.8. FACS Analysis 
 
4% Paraformaldehyde 
-32- 
100ml HBSS were heated to 60-70°C in beaker using heat stirrer. 4g paraformaldehyde were added and after 3-
4 hours of stirring (covered with aluminum foil) the pH was adjusted with NaOH to 7.4. The solution was sterile 
filtrated and stored for maximal 4 weeks at 4°C (protected from light). 
 
Staining Buffer 
HBSS  
25mM Hepes 
5mM MgCl2 
0.1% BSA 
 
Blocking Solution  
5% aggregated rat serum 
Mouse BD FC-Block (1µg/10
6
 cells)  
+up to 10µl with staining buffer 
 
Antibodies Chromophore Company Code/Cat.No. 
anti-mouse CD11c PE/Cy7  BioLegend, Uithoorn, Netherlands 117316 
anti-mouse CD11b A488  BioLegend, Uithoorn, Netherlands 101217 
anti-mouse F4/80 PE BioLegend, Uithoorn, Netherlands 123110 
anti-mouse B220 Pacific Blue BD Biosciences, San Diego, CA 558108 
anti-mouse NK1.1 A488  BioLegend, Uithoorn, Netherlands 108718 
anti-mouse DX5 PE BioLegend, Uithoorn, Netherlands 108907 
anti-mouse Gr1 APC BioLegend, Uithoorn, Netherlands 108411 
7-AAD viability stain PE BioLegend, Uithoorn, Netherlands 420403 
Mouse BD FC-Block -- BD Biosciences, San Diego, CA 553142 
 
 
Surface Staining for FACS Analysis 
10µl blocking solution were added to 5x105 cells in 50µl staining buffer in 1.5ml tubes, vortexed and 
incubated for 10min on ice. Then 10µl of staining solution (250ng antibody/5x105 cells) was added to 
each sample. After vortexing the samples were incubated 20min at 4°C, protected from light. Two 
washing steps were performed by centrifuging at 5000rpm [Eppendorf Centrifuge 5415r] for 4min at 
4°C and resuspending the pellet in 200µl staining buffer. Stained cells were either used directly for 
FACS analysis or stored over night at 4°C in 1% paraformaldehye prior to analysis. The samples were 
analyzed using FACS Canto 2 and BD´s FACS-Diva Software 6. 
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5. Results 
5.1. In vitro Differentiation and Characterization of Bone Marrow-Derived DCs (BMDCs) 
 
To study functions of TYK2 in DCs and also to quantify the deletion efficiency of the CD11c 
promoter-driven cre recombination, we established and characterized BMDC cultures. For in vitro 
differentiation of mouse bone marrow cells to mDCs, granulocyte macrophage colony-stimulating 
factor (GM-CSF) had to be provided in the culture medium. GM-CSF was produced using cells from a 
mouse myeloma cell line (X63), which secretes GM-CSF under starving conditions. To determine the 
quality of X63 cell-derived GM-CSF, tyrosine 694 (Tyr694) phosphorylation of STAT5 in BMMΦs after 
stimulation with different concentrations of either X63 cell-derived or recombinant GM-CSF 
(rGM-CSF) was determined by Western blot analysis (Fig. 7). 
STAT5-Tyr694 phosphorylation was not detectable in unstimulated BMMΦs, whereas BMMΦs 
showed similar STAT5 phosphorylation levels when stimulated with medium containing 5%, 10% or 
15% X63-conditioned medium. Comparable levels could also be observed when BMMΦ were treated 
with rGM-CSF at different concentrations.  
 
 
Figure 7: GM-CSF induced STAT5 phosphorylation in BMMΦs. Wild type BMMΦs were treated for ten 
minutes with various concentrations of X63-conditioned medium, rGM-CSF or left untreated. Twenty 
microgram of total cell extract per lane were separated by 7% SDS-PAGE and subjected to Western blot 
analysis. Membranes were probed with an anti-phosphoTyr694-STAT5 (P-Stat5), and reprobed with 
anti-STAT5 antibody (Stat5). Protein loading was controlled by reprobing with anti-panERK. unst.: 
unstimulated  
 
Since both 5% and 10% X63-conditioned medium prominently induced Stat5 phosphorylation, we 
next tested the capability to drive in vitro differentiation of BMDCs. BMDCs are usually analyzed 
between day 6 and day 8 of in vitro differentiation. Therefore, we decided to compare TYK2fl/fl BMDC 
cultures grown 6 days in the presence of either 5% or 10% of X63-conditioned medium and BMDCs 
cultivated for 8 days using 10% X63-conditioned medium. The purity of the BMDC cultures was 
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analyzed by characterization of the surface expression of CD11c, a prominent DC-cell marker, and 
was determined by FACS analysis (Fig. 8). 
We set a gate according to a viability staining to exclude dead cells from analysis (Fig. 8a and b). On 
day 6 of in vitro differentiation BMDCs cultures grown in 5% X63-conditioned medium contained 
already more than 88% CD11c+ cells (Fig. 8c). The amount of CD11c-expressing cells could not be 
increased by the use of a higher concentration of X63 cell-derived GM-CSF (Fig. 8d) and on average 
no significant difference regarding CD11c expression was observed between these two conditions 
(Fig. 8f). But, as shown in Fig. 8e and 8f, the numbers of CD11c+ cells further increased with time 
since more than 95% of all living cells were expressing CD11c on day eight.  
 
 
Figure 8: FACS analysis of BMDC cultures a) Forward and side scatter analysis of BMDC culture cells. 
The living gate was set according to the viability staining shown in b). b) Dead cells (red) incorporate 
7-AAD due to decreased membrane integrity. Living cells are shown in blue. c)-e) CD11c expression 
in BMDCs after 6 and 8 days in culture. Numbers in quadrants represent the percentage of living 
cells in this quadrant. c)  TYK2
fl/fl
 BMDCs after six days using 5% X63- or d) 10% X63-conditioned 
medium. e) TYK2
fl/fl
 BMDCs after eight days using 10% X63-conditioned medium. f) Mean values ± 
SD of CD11c-expressing cells of 2 mice in 1 experiment for BMDCs at day 6 in 5% X63-conditioned 
medium (d6-5%) and 10% X63-conditioned medium (d6-10%) and 10 mice in 3 experiments for 
BMDCs at day 8 in 10% X63-conditioned medium (d8-10%) are shown. ***: p<0.0002 
 
Next, we characterized BMDC cultures in more detail by analyzing surface expression of CD11c, 
CD11b, B220, F4/80, NK1.1, Gr-1 and DX5 (Fig. 9). BMDCs were analyzed on day 8 of in vitro 
differentiation in 10% X63-conditioned medium, representing the conditions chosen for future 
experiments.  
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Beside high levels of CD11c, approximately 95% of BMDCs also expressed CD11b but not B220 (Fig. 
9a and b), thus representing conventional DCs (CD11c+CD11b+B220-). As expected, hardly any cells 
expressed the NK cell-specific markers DX5 and NK1.1 or F4/80, a marker specific for macrophages 
(Fig. 9c and data not shown). Less than 20% of the cells were Gr-1+, a marker characteristic for pDCs 
and other cell types of the myeloid lineage (Fig. 9d). In summary we could see that BMDCs after 8 
days of differentiation were a homogenous cell population with characteristic mDC marker 
expression (Fig. 9e). 
 
Figure 9: Characterization of unstimulated TYK2
fl/fl
 BMDCs on day 8 of in vitro differentiation. X-axis: 
expression levels of CD11c increase from left to right. Y-axis: expression of surface marker indicated increases 
from bottom to top. Numbers in quadrants represent the percentage of cells in this quadrant. a-d) Figures are 
representative for cells derived from 3 mice in 2 independent experiments. e) Mean values ± SD (3 mice in 2 
independent experiments) of TYK2
fl/fl
 BMDCs positive for the indicated cell surface markers are shown. 
 
5.2. TYK2 mRNA and Protein Levels are Significantly Reduced in TYK2ΔCD11c BMDCs  
 
Cre activity in CD11c-expressing cells, like BMDCs, should lead to deletion of the floxed TYK2 gene in 
these cells. To determine the deletion efficiency, we compared TYK2 mRNA levels of TYK2ΔCD11c to 
TYK2fl/fl and TYK2Δ/Δ BMDCs via RT-quantitative PCR (qPCR)(Fig. 10a) and TYK2 protein levels of the 
same genotypes using IP-Western blot analysis (Fig. 10b and c).  
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As shown in Fig. 10a, we could observe an effective reduction of TYK2 mRNA in TYK2ΔCD11c BMDCs 
compared to TYK2fl/fl mRNA levels. TYK2 mRNA was reduced by 73% on average, even though 
remaining CD11c- cells in the cell culture still made up approximately 5% of all living cells. In TYK2Δ/Δ 
BMDCs TYK2 mRNA was not detectable (Fig. 10a).  
On protein level TYK2 protein was readily detectable in TYK2fl/fl BMDCs and, as expected, was absent 
in TYK2Δ/Δ cells (Fig. 10b). TYK2 protein deletion in TYK2ΔCD11c BMDCs was comparable to data gained 
from mRNA analysis (Fig. 10c). Although it has to be considered, that quantification of Western blot 
pictures is afflicted with increased error rates compared to qPCR analysis, the mean TYK2 reduction 
was calculated with 88% from TYK2fl/fl BMDCs to TYK2ΔCD11c BMDCs (Fig. 10c). JAK1 protein levels 
were analyzed to control IP procedure and they were clearly not influenced by deletion of TYK2 
which is consistent with previous data (Fig. 10b)15, 16. 
Taken together, we could show that TYK2 is reduced drastically in TYK2ΔCD11c BMDCs on mRNA and 
protein level when compared to TYK2fl/fl BMDCs.  
 
 
Figure 10: a) TYK2 mRNA levels in BMDCs. TYK2
fl/fl
 (fl/fl), TYK2
ΔCD11c
 (ΔCD11c) and TYK2
Δ/Δ
 (Δ/Δ) BMDCs 
were analyzed after 8 days of differentiation in 10% X63-conditioned medium. Mean values ± SD of 3 
TYK2
Δ/Δ
, 5 TYK2
fl/fl
 and 6 TYK2
ΔCD11c
 mice in 3 independent experiments were normalized to 1 TYK2
fl/fl
 
mouse (100%). ***: p<0.0001 b) TYK2 and JAK1-IP-Western blot analysis of BMDCs after 8 days of 
differentiation. Protein lysates of 2 mice per genotype were pooled. Results are representative for 3 
individual experiments. Same samples were used for JAK1 IP. c)  TYK2 protein levels in BMDCs were 
quantified with ImageJ 1.45. Mean values ± SD of cells derived from 5 mice per genotype in 3 
independent experiments were normalized to 1 TYK2
fl/fl
 mouse (100%). ***: p<0.0002 
 
5.3. TYK2 mRNA Levels Are Significantly Reduced in CD11c+ TYK2ΔCD11c Splenocytes 
 
The deletion efficiencies observed in BMDC culture might not be reflecting an actual in vivo situation, 
as TYK2 deletion might vary in different DC subsets. Next we determined the efficiency of cre 
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deletion of TYK2 in CD11c-expressing cells in vivo. Spleens of TYK2fl/fl, TYK2ΔCD11c and TYK2Δ/Δ mice 
were isolated and single cell suspensions were positively selected for CD11c expression using 
Magnetic Cell Sorting (MACS). TYK2 mRNA levels of CD11c+ cells were subsequently analyzed via 
RT-qPCR. We found an 87% reduction of TYK2 mRNA levels of CD11c+ TYK2ΔCD11c compared to CD11c+ 
TYK2fl/fl splenocytes on average (Fig. 11).  
In order to examine the effectiveness of the cell enrichment method used, the purity of CD11c+ 
splenocytes was analyzed. The proportion of CD11c-expressing cells after positive selection via MACS 
was determined by FACS analysis. In addition, we conducted one experiment where we performed a 
second round of MACS to quantify the increase of purity from single to double MACSed cell 
populations (Fig. 12). On average 87.9% of single MACSed and 99.2% of double MACSed splenocytes 
were expressing CD11c on the cell surface. Applying a second round of cell sorting clearly increased 
the purity of CD11c+ splenocytes (Fig. 12c).  Since we used single MACSed TYK2ΔCD11c splenocytes to 
determine TYK2 mRNA levels, a reduction of 87.1% of TYK2 mRNA in splenocytes with a purity of 
87.9%, indicated very effective TYK2 deletion in CD11c+ cells. To further characterize CD11c+ 
splenocytes we analyzed surface expression of prominent marker proteins of immune cells similar to 
BMDC characterization (Fig. 13). 
Beside expressing CD11c, FACS analysis of single MACSed splenocytes showed that approximately 
18% of all living cells were expressing B220 (Fig. 12a and 13a). CD11c+B220+ cells likely constitute 
pDCs, whereas CD11c-B220+ represent splenic B-cells. Contrarily to in vitro differentiated mDCs, 
splenic CD11c+ cells were CD11b+ or CD11b- (Fig. 13b). Although pDCs also do not express CD11b, the 
negative population for this marker might in addition be constituted by splenic mDCs, which can be, 
depending on the subtype, either CD11b positive or negative108. In agreement with previous studies, 
freshly isolated splenic DCs were F4/80+ (Fig. 13c)109. DX5 was not expressed, with the exception of a 
small population of CD11c+DX5low cells (Fig. 13d). CD11c+DX5low cells were probably 
NK/NKT-progenitor cells, because the second NK-cell specific marker NK1.1 was not yet expressed on 
those cells (data not shown) 110. Gr-1 could be found on 31% of CD11c+-enriched splenocytes (Fig. 
13e). In addition to granulocytes and some myeloid progenitor cells, low amounts of Gr-1 can also be 
expressed on DCs102, 111. Overall we could detect about 80% mDCs (CD11c+CD11b±F4/80+), 10% pDCs 
(CD11clowB220+CD11b-) and 10% of other cells which probably consist of B-cells, T-cells, NK/NKT-cells 
and macrophages. Importantly, marker distribution was not dependent on the genotype of mice 
analyzed (Fig. 13f). 
In summary, we could observe a very effective TYK2 deletion as TYK2 mRNA was reduced by 87% 
from TYK2fl/fl to TYK2ΔCD11c CD11c+ splenocytes in cell fractions with a purity of 88%. Although the 
majority (80%) of single MACSed CD11c+ splenocytes showed characteristic mDC marker expression,  
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it has to be kept in mind, that a second MACSing step should be performed if a higher purity of 
CD11c+ splenocytes is required. 
 
 
Figure 11: TYK2 mRNA levels of CD11c
+
 fractions of TYK2
ΔCD11c
 and TYK2
fl/fl
 splenocytes are shown. 
Mean values ± SD of cells derived from 6 mice per genotype in 3 independent experiments were 
normalized to 1 TYK2
fl/fl
 mouse ***: p<0.0001; fl/fl: TYK2
fl/fl
;  ΔCD11c: TYK2
ΔCD11c
 
 
 
Figure 12: CD11c expression in CD11c
+
 fractions of MACSed splenocytes. CD11c expression increases from 
left to right. a) Single MACSed splenocytes. Data shown are representative for 12 mice in 3 independent 
experiments. b) Double MACSed splenocytes representative for 2 mice in 1 experiment. c) Mean values ± SD 
of CD11c-expressing cells of single (1x) and double (2x) MACSed splenocytes are shown ***: p<0.0001 
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Figure 13: Characterization of single MACSed CD11c
+ 
splenocytes. X-axis: expression levels of CD11c increase 
from left to right. Y-axis: expression of surface marker indicated increases from bottom to top. Figures are 
representative for 12 mice in 2 independent experiments. f) Mean values ± SD of splenocytes positive for the 
indicated cell surface markers of 3 mice in 2 independent experiments for TYK2
fl/fl 
(fl/fl) and TYK2
ΔCD11c
 (ΔCD11c) 
and 2 mice in 2 experiments for TYK2
Δ/Δ 
(Δ/Δ) are shown. 
 
5.4. MCMV Replicates to Higher Titers in TYK2ΔCD11c BMDCs in vitro Compared to TYK2fl/fl 
BMDCs 
 
It has been shown previously in our lab that macrophages, in contrast to what is known from 
fibroblasts, are very resistant against MCMV infection. This resistance is mediated by 
autocrine/paracrine IFN-α/β signaling and depends on the presence of TYK224. In order to test if this 
is also true for DCs, we analyzed MCMV replication in TYK2ΔCD11c BMDCs and compared it to TYK2fl/fl 
and TYK2Δ/Δ BMDCs. Viral titers were determined 0, 1, 3 and 5 days post infection by using plaque 
forming assays (Fig. 14). Right after infection MCMV titers of all three genotypes were similar, 
indicating equal binding and entry of MCMV particles into the cells. MCMV replicated poorly in 
TYK2fl/fl BMDCs compared to TYK2Δ/Δ BMDCs. Three and five days post infection the MCMV titers 
were 100-fold higher in TYK2Δ/Δ BMDCs than in TYK2fl/fl cells. MCMV titers in TYK2ΔCD11c BMDC were 
increased 10-fold when compared to TYK2fl/fl BMDCs. The difference to TYK2Δ/Δ BMDCs might come 
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from a contribution of other (CD11c-) cells in the culture or from ineffective TYK2 deletion in DCs 
(TYK2 deletion efficiency in BMDCs approx. 75% s. Fig. 10, purity of population approx. 95% s. Fig. 8).  
In summary, we could see that the MCMV resistance of BMDC was clearly dependent on TYK2 and 
that small amounts of remaining TYK2 in TYK2ΔCD11c are sufficient to have an impact on MCMV 
resistance. 
 
 
Figure 14: TC-MCMV replication in BMDCs. BMDCs of the indicated genotypes were 
infected with TC-MCMV (MOI=5). TC-MCMV titers were determined 0, 1, 3 and 5 days 
post infection by plaque forming assays. 1 representative out of 3 independent 
experiments is shown. fl/fl: TYK2
fl/fl
; ΔCD11c: TYK2
ΔCD11c
; Δ/Δ: TYK2
Δ/Δ
 
 
5.5. TYK2-Dependent STAT1/2 Activation in TYK2ΔCD11c BMDCs After MCMV Infection 
 
Infection with MCMV most likely results in an IFN type I induced activation of STAT1 and STAT2 in 
BMDCs, as DCs produce a lot of IFN-α/β in response to MCMV infection and are responsive to type I 
IFN treatment77, 112, 113. Due to the lack of TYK2 in TYK2ΔCD11c BMDCs, MCMV-induced IFN signaling 
could be affected. Therefore, STAT1 and STAT2 phosphorylation was determined after 0, 2 and 5 
hours post infection with TC-MCMV using Western blot analysis (Fig. 15). 
In agreement with previous studies on BMMΦs24, STAT1 and STAT2 protein levels were decreased in 
TYK2Δ/Δ BMDCs. In TYK2fl/fl BMDCs Tyr701 phosphorylation of STAT1 was detected right after 
infection with MCMV (30min), was slightly increased after 2 hours and started to decline 5 hours 
post infection. In contrast, STAT1 phosphorylation in TYK2Δ/Δ BMDCs was hardly detectable 
immediately after infection, whereas similar to TYK2fl/fl BMDCs the phosphorylation signal was 
increased after 2 and back to basal levels 5 hours post infection. TYK2ΔCD11c BMDCs resembled the 
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situation observed in TYK2Δ/Δ BMDCs, except that the induction of STAT1 phosphorylation was 
slightly higher. The kinetics of STAT2 Tyr689 phosphorylation in TYK2fl/fl, TYK2Δ/Δ and TYK2ΔCD11c 
BMDCs were similar to STAT1 phosphorylation. Although STAT2 phosphorylation was still induced 
significantly in TYK2Δ/Δ and TYK2ΔCD11c BMDCs it did not reach TYK2fl/fl levels. 
Type I IFN response upon MCMV infection induces upregulation of STAT1 and STAT2 proteins. 
Decreased activation of STAT1/2 genes due to impaired TYK2 functions in DCs would lead to 
decreased levels of STAT1 and STAT2 later in MCMV infection. Additionally, MCMV was reported to 
directly degrade STAT2 in fibroblasts83. To analyze STAT1 and STAT2 protein levels in BMDCs at later 
time points of MCMV infection, we performed Western blot analysis with whole cell extracts 0, 1, 3 
and 5 days post infection (Fig. 16). As seen previously, STAT1 and STAT2 levels of TYK2ΔCD11c and 
TYK2Δ/Δ BMDCs were reduced right after MCMV infection (30min) compared to TYK2fl/fl cells. In 
TYK2fl/fl BMDCs STAT1 levels were increased on day 1 and 3 and slightly declined on day 5 post 
infection. STAT1 protein levels in TYK2Δ/Δ BMDCs were also increased on day 1 and 3 post infection, 
but were significantly lower than protein levels in TYK2fl/fl cells. Surprisingly, although STAT1 levels in 
TYK2ΔCD11c were decreased to levels observed in TYK2Δ/Δ cells immediately after infection, within 24 
hours they reached TYK2fl/fl levels and remained high until day 5 post infection. STAT2 levels were 
similar to STAT1, except for day 5, where STAT2 levels of all three genotypes were decreased to 
equal amounts. Remarkably, STAT2 protein was detectable in all genotypes 5 days post infection, 
although MCMV titers were increased 100-fold in TYK2Δ/Δ BMDCs compared to TYK2fl/fl cells. Thus, 
similar to what was reported in BMMΦs, MCMV infection does not lead to a detectable STAT2 
degradation in BMDCs24. 
 
Taken together, early after MCMV infection we could observe decreased STAT1 and STAT2 
phosphorylation in TYK2ΔCD11c and TYK2Δ/Δ BMDCs compared to TYK2fl/fl cells, which might be partially 
caused by lower basal levels of these proteins. In contrast to TYK2Δ/Δ BMDCs, STAT1 and STAT2 
protein expression reached wild type levels in TYK2ΔCD11c cells on day 1 post infection. STAT1/2 
phosphorylation of TYK2ΔCD11c BMDCs was intermediate between TYK2fl/fl and TYK2Δ/Δ. Intermediate 
STAT1/2 phosphorylation of TYK2ΔCD11c BMDCs is consistent with intermediate MCMV replication in 
those cells in the previous experiments. 
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Figure 15: Tyrosine phosphorylation of STAT1 and STAT2 after TC-MCMV infection; BMDCs 
were infected with MCMV (MOI=5). At indicated times cells were lysed, separated with 
SDS-PAGE (6.5%, 20µg total cell extract per lane) and subjected to Western blot analysis. 
Membranes were probed with the indicated antibodies specific for phosphorylated Tyr701 
of STAT1 (P-STAT1), phosphorylated Tyr689 of STAT2 (P-STAT2), STAT1 (STAT1) or STAT2 
protein (STAT2). Protein loading was controlled by re-probing with anti-ERK antibody 
(panERK). The figure is representative for 2 individual experiments. fl/fl: TYK2
fl/fl
; ΔCD11c: 
TYK2
ΔCD11c
; Δ/Δ: TYK2
Δ/Δ
 
 
 
Figure 16: STAT1 and STAT2 expression in BMDCs of indicated genotypes after TC-MCMV 
infection (MOI=5); At indicated times cells were lysed, separated with SDS-PAGE (6.5%, 
20µg total cell extract per lane) and subjected to Western blot analysis. Membranes were 
probed with the indicated antibodies specific for STAT1 protein (STAT1) or STAT2 protein 
(STAT2). Protein loading was controlled by re-probing with anti-ERK antibody (panERK). 
The figure is representative for cells derived from 2 mice per genotype in 1 experiment. 
fl/fl: TYK2
fl/fl
; ΔCD11c: TYK2
ΔCD11c
; Δ/Δ: TYK2
Δ/Δ
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5.6. Contribution of TYK2 in DCs, Macrophages/Neutrophils and T-Cells to MCMV Defense 
 
It has been reported by our group that TYK2 knockout mice showed impaired clearance of MCMV 
from organs24. In order to test our hypothesis that TYK2 in macrophages and DCs contributes to early 
innate immune responses, we investigated the consequences of cell type-specific TYK2 deletion 
during MCMV infection. TYK2fl/fl, TYK2ΔCD11c, TYK2ΔLysM and TYK2Δ/Δ mice were infected with a sublethal 
dose of MCMV and virus replication/clearance was determined in livers. In addition to the deletion of 
TYK2 in macrophages/neutrophils (TYK2ΔLysM) or DCs (TYK2ΔCD11c), we included T-cell specific TYK2 
knockout mice (TYK2ΔLck) in order to exclude contributions of TYK2 in T-cells to the early anti-MCMV 
response.  Viral titers were determined in livers at three and seven days post infection. As shown in 
Fig. 17a, viral titers were increased around five-fold in the absence of TYK2 at three days post 
infection. Increased viral titers were also found in livers from TYK2ΔCD11c mice, whereas the virus load 
appeared unchanged in livers from TYK2ΔLysM and TYK2ΔLck mice. Again, by using a higher infection 
dose (2.5x105 pfu/mouse), elevated MCMV titers could be found in livers of TYK2Δ/Δ mice, but no 
significant differences between TYK2fl/fl , TYK2ΔCD11c, TYK2ΔLysM and TYK2ΔLck mice were observed three 
days post infection (Fig. 17c). We also observed an increase of experimental variation from lower to 
higher infection doses used for experiments (Fig. 17a and c). In contrast to what has been shown 
previously24, MCMV was almost entirely cleared from livers on day seven post infection irrespective 
of the genotype and the infection dose (Fig. 17b and d). Other reports demonstrated that MCMV 
titers remain high in livers up to seven days post infection 114 and the reason for the discrepancy is 
unclear.  
In summary, these data indicate an impact of TYK2 in DCs on the control of MCMV replication and/or 
clearance in livers early after infection and no contribution of TYK2 in macrophages/neutrophils and 
T-cells. However, the differences were small and data need to be confirmed (higher sample size). In 
parallel, virus titrations of spleen, lung and salivary gland homogenates of these mice (done by 
Michael Rammerstorfer in the laboratory), indicate a requirement of TYK2 in 
macrophages/neutrophils and DCs for the control of MCMV in salivary glands seven days post 
infection (Fig. 18a and b). Virus titers in spleen and lungs were too low for conclusive analysis (data 
not shown). 
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Figure 17: Virus titer in livers of TC-MCMV infected mice. MCMV titers were determined by plaque forming 
assays 3 (a/c) and 7 (b/d) days post infection. 1 dot represents 1 mouse and green/blue dots represent the 2 
individual experiments. a) and b) Mice were infected with 5x10
4
 pfu/mouse. Mean values ± SD of 6 mice in 2 
experiments are shown, except for ΔLck and ΔCD11c (3 mice in 1 experiment). *: p<0.025 c) and d) Mice were 
infected with 2.5x10
5
 pfu/mouse. Mean values ± SD of 3 mice in 1 experiment are shown. *: p<0.04; D.L.: 
detection limit; p.i.: post infection; pfu: plaque forming units 
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Figure 18: Virus titer in salivary glands of MCMV infected mice. MCMV titers were determined by plaque 
forming assays 7 days post infection. 1 dot represents1 mouse and green/blue dots represent 2 individual 
experiments. a) Mice were infected with 5x10
4
 pfu/mouse. Mean values ± SD of 6 mice in 2 experiments are 
shown, except for ΔLck and ΔCD11c (3 mice in 1 experiment). b) Mice were infected with 2.5x10
5
 pfu/mouse. 
Mean values ± SD of 6 mice in 2 experiment are shown. *: p<0.021; ***: p<0.0006; Data from Michael 
Rammerstorfer; D.L.: detection limit; p.i.: post infection; pfu: plaque forming units 
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6. Discussion 
 
The aims of this work about “cell type-specific functions of TYK2 in the antiviral defense against 
MCMV” were to characterize TYK2ΔCD11c mice with respect to TYK2 deletion efficiencies in DCs and to 
analyze the effect on anti-MCMV defense. We established a BMDC culture protocol and showed that 
more than 95% of our BMDCs were expressing CD11c on day 8 of in vitro differentiation. TYK2 mRNA 
in TYK2ΔCD11c cells was reduced by 75% when compared to TYK2fl/fl BMDCs and a similar reduction 
could be detected by Western blot analysis for TYK2 protein. In CD11c+ splenocytes we observed a 
reduction of 87% of TYK2 mRNA from TYK2fl/fl to TYK2ΔCD11c cells in populations where 88% of the 
living cells were expressing CD11c. These results are comparable to what was published previously. 
In the initial characterization of the CD11c/cre mice, Caton et al. could see recombination of the 
floxed allele from about 51% in CD11clow to about 96% in CD11chigh splenocytes87. Using almost the 
same analyzing methods that we used in this work, but targeting STAT3, one group reported deletion 
efficiencies of 70% and 90% in BMDCs and splenic DCs respectively115. 
When we investigated the replication of MCMV in BMDCs, we could find a clear impact of 
CD11c-cre-mediated TYK2 deletion. MCMV titers in TYK2CD11c BMDCs was around 10-fold higher 
than in TYK2fl/fl controls. However, MCMV replication was lower than in BMDCs derived from TYK2/ 
mice. This difference may be explained by the incomplete deletion of TYK2, as BMDCs still containing 
TYK2 might additionally have a survival/proliferative advantage during MCMV infection. Further 
insights might be gained by analyzing cell purity and deletion efficiency of TYK2 after 5 days of 
infection with MCMV. Notably, BMDCs appeared generally more sensitive to MCMV infection than 
what has been shown for macrophages24, however, a direct comparison was not performed. 
Tyrosine phosphorylation of STAT1 and STAT2 was reduced in TYK2ΔCD11c and TYK2Δ/Δ BMDCs 
compared to TYK2fl/fl BMDCs until 5 hours post infection with MCMV. This may in part be caused by 
the reduced basal protein levels of STAT1 and STAT2 in cells of these genotypes. This is similar to 
what was seen in macrophages24. Interestingly, slightly higher STAT1/2 phosphorylation in TYK2ΔCD11c 
BMDCs seems to be sufficient to induce STAT1/2 expression to levels observed in TYK2fl/fl cells at 1 
day post infection. Since STAT1/2 upregulation upon MCMV infection seems to be TYK2-dependent 
and the majority of TYK2ΔCD11c BMDCs should not express TYK2, we expected to see a more 
pronounced difference between TYK2ΔCD11c BMDCs and TYK2fl/fl BMDCs. A possible explanation might 
again be that BMDCs still expressing TYK2 are accumulated during MCMV infection due to a 
protective or proliferative advantage. Other cells, not expressing CD11c, might also contribute to this 
observation. Nevertheless, both MCMV replication and activation of STAT1 and STAT2 were clearly 
affected by the DC-specific TYK2 deletion in BMDC cultures in vitro.  
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In vivo we could show that TYK2 in DCs has an impact on MCMV defense in livers as MCMV titers 
were elevated 3 days post infection in TYK2ΔCD11c mice compared to TYK2fl/fl mice. In salivary glands, a 
similar effect could be found after 7 days of infection in TYK2ΔCD11c and TYK2ΔLysM mice. These data 
indicate an organ-specific TYK2 dependence in the defense against MCMV of at least 
macrophages/neutrophils and DCs, but this requires confirmation. Nevertheless, these findings 
refine the current picture of early host defense mechanisms during MCMV infections. In livers, 
macrophage-specific TYK2 deficiency did not elevate MCMV levels. Although macrophages definitely 
have a role in MCMV defense in the liver, their major function is the recruitment of NK-cells. 
Whether or not this is affected in TYK2LysM mice remains to be investigated. TYK2 deletion in DCs 
clearly has an impact on controlling MCMV infection in livers. Reasons therefore might be that 
elevated MCMV replication in infected resident DCs lacking TYK2 is able to overcome NK-cell 
dependent anti-MCMV response. In addition, killing of DCs by MCMV might lead to decreased 
IFN-α/β production and therefore reduce NK-cell responses. Furthermore, TYK2 deficiency in DCs 
could lead to impaired effector cell recruitment to the liver. The same might also apply for salivary 
glands 7 days post infection. Further insights in cell type-specific TYK2 functions in the ultimate 
control of MCMV in vivo will come from survival experiments which are currently run. 
In addition to these findings we observed almost entire MCMV clearance from livers in all tested 
genotypes 7 days post infection. In similar experiments, MCMV titers in livers were steadily 
increasing from day 7 to day 28 post infection24. Furthermore and again in contrast to previous data, 
MCMV titers in our experiments were comparably low and often close to the detection limit. Reasons 
are unclear, but might include the different hygiene status/housing conditions of the mice or 
differences in handling and determination of virus titers.  
In summary, using conditional TYK2 knockout mice, we could demonstrate a requirement of TYK2 in 
DCs to counteract MCMV infection in vitro and in vivo. Additional experiments will be required to 
substantiate these findings and to reveal the underlying mechanisms. 
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Frequently Used Abbreviations 
 
APC antigen presenting cell 
BMDC bone marrow-derived dendritic cell 
CTL cytotoxic T-lymphocyte 
DC dendritic cell 
HCMV human cytomegalovirus 
IFN interferon 
IFNAR interferon-α/β receptor 
IL interleukin 
IP  intraperitoneal 
IRF interferon regulatory factor 
ISG interferon stimulated gene 
JAK Janus kinase 
MCMV murine cytomegalovirus 
mDC myeloid dendritic cell 
MHC major histocompatibility complex 
NK-cell natural killer cell 
PAMP pathogen-associated molecular pattern 
pDC plasmacytoid dendritic cell 
PRR pattern-recognition receptor 
SG salivary gland 
SNP single nucleotide polymorphism 
STAT signal transducer and activator of transcription 
TC tissue culture 
TLR Toll-like receptor 
TYK2 tyrosine kinase 2 
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